Adults 18 to 65, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Assessement of SafetyPrimary· 140 days
• Proportion of volunteers with vaccine related serious adverse events (SAEs) collected up to day 140 after enrollment.
Group
Value
95% CI
ChAdOx1.tHIVconsv1 Low Dose
0
ChADOx1.tHIVconsv1 Higher Dose
0
Assement of SafetyPrimary· up to 28 days after each vaccination
Proportion of volunteers with Grade 3 or 4 unsolicited adverse events (AEs) through 28 days post final vaccination
Group
Value
95% CI
ChAdOx1.tHIVconsv1 Low Dose
0
ChADOx1.tHIVconsv1 Higher Dose
6
Assessment of SafetyPrimary· up to day 7
Proportion of volunteers with local and systemic reactogenicity events from Day 0 to Day 6 post vaccination
Group
Value
95% CI
ChAdOx1.tHIVconsv1 Low Dose
3
ChADOx1.tHIVconsv1 Higher Dose
10
Assessment of the Immunogenicity of the ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3 & 4 Vaccines Administered Sequentially.Secondary· Up to 5 months
The proportion of participants that develop T-cell responses to tHIVconsvx measured by IFN-gamma ELISpot assay
Group
Value
95% CI
ChAdOx1.tHIVconsv1 Low Dose
3
ChADOx1.tHIVconsv1 Higher Dose
10
Adverse events — posted to ClinicalTrials.gov
Time frame: Study visits for safety evaluations occurred 1, 7, 14 and 28 days after each vaccination, with additional visits up to days 112 and 140 in Groups 1 and 2, respectively. Safety data included specified, solicited symptoms, collected up to day 7 after each vaccination; unsolicited AEs, collected up to day 28 after each vaccination; and SAEs collected until the end of the study. Blood samples for the evaluation of biochemical and/or haematological parameters were taken at selected study visits..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.
In addition, the study will assess the immune responses generated of the candidate vaccines ChAdOx1.tHIVconsv1, MV.tHIVconsv3 and MVA.tHIVconsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.
3 healthy, HIV-1 negative adult volunteers will receive one vaccination of low dose ChAdOx1.tHIVconsv1. A further 10 healthy, HIV-1 negative adult volunteers will receive a higher dose of ChAdOx1.tHIVconsv1, followed by one vaccination each of MVA.tHIVconsv3 and MVA.tHIVconsv4 4 weeks later.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor
· Phase 2
· recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
· Phase 2
· recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV
· NA
· recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i
· Phase 1
· recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
· Phase 1
· recruiting
Other University of Oxford trials
Trials by the same sponsor.
NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
· Phase 2
· not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults
· Phase 1
· not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis
· not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE
· Phase 3
· not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 29 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04586673.